Risks
4 risks
Risk Intelligence
Prolonged weakness in European chemical/pharma markets
View Risks →
GMM Pfaudler Limited — Q3 FY26
GMM Pfaudler reported a stable Q3 FY26 with revenue and profitability in line with expectations, but the highlight was a strong order intake of ₹961 crore (+9% QoQ, +20% YoY), driving the backlog to a record ₹2,205 crore (+27% YoY).
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
GMM Pfaudler reported a stable Q3 FY26 with revenue and profitability in line with expectations, but the highlight was a strong order intake of ₹961 crore (+9% QoQ, +20% YoY), driving the backlog to a record ₹2,205 crore (+27% YoY). The 9-month revenue grew 8% YoY and EBITDA rose 14% YoY, with margins improving to 12.7% (9M basis) from 12% last year. Diversification into non-traditional sectors (defense, nuclear, metals) now accounts for 50% of orders, offsetting weakness in chemicals and Europe. Management expects Q4 to be strong in India and maintains a medium-term EBITDA margin target of 16-18%, though near-term headwinds from global uncertainty and underperforming units (Germany, China) persist. Key risk: a prolonged downturn in European chemical/pharma markets could delay margin recovery.
जीएमएम पफौडलर की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) में कमाई और मुनाफा उम्मीद के मुताबिक रहा। सबसे अच्छी बात यह रही कि कंपनी को 961 करोड़ रुपये के नए ऑर्डर मिले, जो पिछली तिमाही से 9% और पिछले साल से 20% ज़्यादा हैं। इससे बकाया ऑर्डर (बैकलॉग) बढ़कर 2,205 करोड़ रुपये हो गया। नौ महीने में कमाई 8% और मुनाफा (EBITDA) 14% बढ़ा। मुनाफे की दर 12% से सुधरकर 12.7% हो गई। कंपनी अब रसायन के अलावा रक्षा, परमाणु और धातु जैसे नए क्षेत्रों में भी काम कर रही है, जहाँ से 50% ऑर्डर आ रहे हैं। प्रबंधन को चौथी तिमाही में भारत में अच्छी वृद्धि की उम्मीद है और 16-18% मुनाफे का लक्ष्य है। लेकिन यूरोप और चीन में कमजोरी से जोखिम बना हुआ है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Order Intake (Q3)
₹961 Cr
+20% YoY
Strong order intake driven by non-traditional sectors; India contributed ~₹290 Cr, international ~₹671 Cr.
Order Backlog
₹2,205 Cr
+27% YoY
Record backlog provides strong revenue visibility for FY27; India backlog ₹550 Cr, international ₹1,655 Cr.
Non-Traditional Order Share
50%
+8pp YoY
Orders from non-chemical/pharma sectors now half of total, up from ~30% 18 months ago.
Germany Cost Savings (Annualized)
₹25 Cr
N/A
Full-year savings from German restructuring expected by FY27; 30% wage bill reduction.
Fast read
Guidance and risk preview
Management reiterated the target from the capital markets day, driven by higher-margin mixing and systems businesses and turnaround of underperform...
Europe remains slow and uncertain, especially in traditional chemical and pharma segments, which could delay margin recovery.
View Risks →